PURPOSE OR REVIEW: There is a large body of evidence supporting the efficacy of low-level laser therapy (LLLT) also known as PhotoBioModulation (PBM) when used for the prevention and/or treatment of oral mucositis in patients undergoing radiotherapy for head and neck cancer, or high-dose chemotherapy regimens. This review aims at giving the state of the art of this technique in this indication. RECENT FINDINGS: Recent advances in LLLT/PBM technology, together with a better understanding of mechanisms involved and dosimetric parameters may lead to the management of a broader range of complications associated with cancer treatment. This could enhance patient adherence to cancer therapy, and improve quality of life and treatment outcomes. SUMMARY: The article discusses LLLT/PBM mechanisms of action, dosimetry, and safety, and aims to identify some cancer treatment side-effects for which LLLT/PBM may prove to be effective (oral mucositis, radiation dermatitis, lymphedema). In addition, LLLT/PBM parameters for each of these complications are suggested and future research directions are discussed.
PURPOSE OR REVIEW: There is a large body of evidence supporting the efficacy of low-level laser therapy (LLLT) also known as PhotoBioModulation (PBM) when used for the prevention and/or treatment of oral mucositis in patients undergoing radiotherapy for head and neck cancer, or high-dose chemotherapy regimens. This review aims at giving the state of the art of this technique in this indication. RECENT FINDINGS: Recent advances in LLLT/PBM technology, together with a better understanding of mechanisms involved and dosimetric parameters may lead to the management of a broader range of complications associated with cancer treatment. This could enhance patient adherence to cancer therapy, and improve quality of life and treatment outcomes. SUMMARY: The article discusses LLLT/PBM mechanisms of action, dosimetry, and safety, and aims to identify some cancer treatment side-effects for which LLLT/PBM may prove to be effective (oral mucositis, radiation dermatitis, lymphedema). In addition, LLLT/PBM parameters for each of these complications are suggested and future research directions are discussed.
Authors: Mariana de Pauli Paglioni; Carolina Guimarães Bonfim Alves; Elisa Kauark Fontes; Marcio Ajudarte Lopes; Ana Carolina Prado Ribeiro; Thaís Bianca Brandão; Cesar Augusto Migliorati; Alan Roger Santos-Silva Journal: Support Care Cancer Date: 2019-07-01 Impact factor: 3.603
Authors: Elisa Kauark-Fontes; Cesar Augusto Migliorati; Joel B Epstein; Nathaniel Simon Treister; Carolina Guimarães Bonfim Alves; Karina Morais Faria; Natalia Rangel Palmier; Leticia Rodrigues-Oliveira; Mariana de Pauli Paglioni; Luiz Alcino Monteiro Gueiros; Karina G M da Conceição Vasconcelos; Gilberto de Castro; Adriana Franco Paes Leme; Marcio Ajudarte Lopes; Ana Carolina Prado-Ribeiro; Thaís Bianca Brandão; Alan Roger Santos-Silva Journal: Support Care Cancer Date: 2021-10-28 Impact factor: 3.603
Authors: Jolien Robijns; Raj G Nair; Joy Lodewijckx; Praveen Arany; Andrei Barasch; Jan M Bjordal; Paolo Bossi; Anne Chilles; Patricia M Corby; Joel B Epstein; Sharon Elad; Reza Fekrazad; Eduardo Rodrigues Fregnani; Marie-Thérèse Genot; Ana M C Ibarra; Michael R Hamblin; Vladimir Heiskanen; Ken Hu; Jean Klastersky; Rajesh Lalla; Sofia Latifian; Arun Maiya; Jeroen Mebis; Cesar A Migliorati; Dan M J Milstein; Barbara Murphy; Judith E Raber-Durlacher; Hendrik J Roseboom; Stephen Sonis; Nathaniel Treister; Yehuda Zadik; René-Jean Bensadoun Journal: Front Oncol Date: 2022-08-30 Impact factor: 5.738
Authors: René-Jean Bensadoun; Joel B Epstein; Raj G Nair; Andrei Barasch; Judith E Raber-Durlacher; Cesar Migliorati; Marie-Thérèse Genot-Klastersky; Nathaniel Treister; Praveen Arany; Joy Lodewijckx; Jolien Robijns Journal: Cancer Med Date: 2020-10-26 Impact factor: 4.452